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Summary
Background Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to 
classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is increasingly 
prescribed for these patient populations despite scarcity of evidence of clinical effectiveness or cost-effectiveness. We 
aimed to compare the long-term clinical effectiveness and cost-effectiveness of levetiracetam compared with valproate 
in participants with newly diagnosed generalised or unclassifiable epilepsy.
Methods We did an open-label, randomised controlled trial to compare levetiracetam with valproate as first-line treatment 
for patients with generalised or unclassified epilepsy. Adult and paediatric neurology services (69 centres overall) across 
the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked generalised 
or unclassifiable seizures. Participants were randomly allocated (1:1) to receive either levetiracetam or valproate, using a 
minimisation programme with a random element utilising factors. Participants and investigators were aware of 
treatment allocation. For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per 
day for levetiracetam and valproate, and for children aged 5–12 years, the initial daily maintenance doses advised were 
25 mg/kg for valproate and 40 mg/kg for levetiracetam. All drugs were administered orally. SANAD II was designed to 
assess the non-inferiority of levetiracetam compared with valproate for the primary outcome time to 12-month remission. 
The non-inferiority limit was a hazard ratio (HR) of 1·314, which equates to an absolute difference of 10%. A HR greater 
than 1 indicated that an event was more likely on valproate. All participants were included in the intention-to-treat (ITT) 
analysis. Per-protocol (PP) analyses excluded participants with major protocol deviations and those who were subsequently 
diagnosed as not having epilepsy. Safety analyses included all participants who received one dose of any study drug. This 
trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64).
Findings 520 participants were recruited between April 30, 2013, and Aug 2, 2016, and followed up for a further 2 years. 
260 participants were randomly allocated to receive levetiracetam and 260 participants to receive valproate. The ITT 
analysis included all participants and the PP analysis included 255 participants randomly allocated to valproate and 
254 randomly allocated to levetiracetam. Median age of participants was 13·9 years (range 5·0–94·4), 65% were male 
and 35% were female, 397 participants had generalised epilepsy, and 123 unclassified epilepsy. Levetiracetam did not 
meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission (HR 1·19 [95% CI 0·96–1·47]); 
non-inferiority margin 1·314. The PP analysis showed that the 12-month remission was superior with valproate than 
with levetiracetam. There were two deaths, one in each group, that were unrelated to trial treatments. Adverse reactions 
were reported by 96 (37%) participants randomly assigned to valproate and 107 (42%) participants randomly assigned to 
levetiracetam. Levetiracetam was dominated by valproate in the cost-utility analysis, with a negative incremental net 
health benefit of –0·040 (95% central range –0·175 to 0·037) and a probability of 0·17 of being cost-effectiveness at a 
threshold of £20 000 per quality-adjusted life-year. Cost-effectiveness was based on differences between treatment 
groups in costs and quality-adjusted life-years.
Interpretation Compared with valproate, levetiracetam was found to be neither clinically effective nor cost-effective. 
For girls and women of child-bearing potential, these results inform discussions about benefit and harm of avoiding 
valproate.
Funding National Institute for Health Research Health Technology Assessment Programme.
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Introduction
Epilepsy is a common condition with a prevalence of 
0·5–1% and lifetime incidence of up to 5%.1,2 It is also a 
complex condition with many different causes and 
several seizure types and syndromes, as defined by the 
International League Against Epilepsy.3,4 Epilepsy is 
uniquely stigmatising and negatively affects quality of 
life (QOL), education, and employment prospects.5,6
Around a third of people with epilepsy have idiopathic 
generalised epilepsy, also referred to as genetic generalised 
epilepsy, which includes several syndromes classified 
according to seizure types and age of onset, such as 
childhood absence epilepsy and juvenile myoclonic 
epilepsy.4 Although differing syndromes are recognised, 
prognostic modelling of data from the first Standard 
And New Antiepileptic Drug (SANAD I)7 study indicates 
that relative treatment responses are consistent across 
syndromes. Also, at the time of diagnosis, some people 
cannot be classified as having either a focal or generalised 
epilepsy, although for many a syndromic diagnosis can be 
made, usually following further investigation or as more 
seizures are witnessed.8,9
Valproate is currently recommended as a first-line 
treatment for generalised and for unclassifiable epilepsy 
as it has a broad spectrum of action,10 although there is 
little evidence from randomised controlled trials (RCTs) 
to support this recommendation. Cochrane reviews have 
not found superiority of valproate over other anti -seizure 
mediations11–13 and highlight problems with epilepsy 
classification and sample size of studies analysed. 
SANAD I identified valproate as a clinically and cost-
effective alternative to either lamotrigine or topiramate,14 
and a double-blind trial15 of 16 week therapy in childhood 
and juvenile absence epilepsy found valproate and 
ethosuximide superior to lamotrigine for time to treat-
ment failure.
Levetiracetam has been increasingly used as first-line 
treatment in both focal and generalised epilepsy, 
particularly for women of childbearing age with a 
generalised epilepsy. Although there is evidence from 
Research in context
Evidence before this study
At the time of the design of this trial (SANAD II), valproate was 
recommended as a first-line treatment for patients with newly 
diagnosed generalised epilepsy, which includes syndromes such 
as absence epilepsies, juvenile myoclonic epilepsy, and 
generalised epilepsy with tonic-clonic seizures on waking, and for 
unclassified epilepsy. The evidence base from randomised 
controlled trials to support this recommendation was scarce, 
partly because valproate became accepted as a first-line 
treatment in an era before rigorous trials were undertaken. 
The first SANAD trial (published in 2007) identified valproate as a 
clinically effective and cost-effective first-line treatment 
compared with lamotrigine and topiramate. Prognostic 
modelling of data from SANAD also found similar treatment 
responses in the differing epilepsy types. A 14-week double-blind 
randomised trial in patients with absence epilepsies found 
valproate and ethosuximide superior to lamotrigine for 
treatment failure. A Cochrane review identified possible 
confounding in previous studies due to misclassification of focal 
epilepsy as generalised epilepsy. That review included an 
individual participant network meta-analysis, which found no 
evidence of superiority of valproate over other treatments for 
seizure control, but valproate was superior to carbamazepine, 
topiramate, and phenobarbital for treatment failure.
Valproate had also been identified as teratogenic and is 
associated with around a 10% major malformations rate and 
with around a third of children exposed to valproate in utero 
having a significant reduction in IQ. During the conduct of 
SANAD II, the European Medicines Agency and the Medicines 
for Healthcare Regulatory Authority implemented a pregnancy 
prevention programme. Treatment decisions are now 
particularly difficult for women and girls with generalised 
epilepsy, which typically starts during childhood and 
adolescence. The main alternatives to valproate are lamotrigine, 
which is less effective than valproate, and levetiracetam, which 
previously had unknown effectiveness compared with valproate 
as no head-to-head randomised trials had been undertaken.
Added value of this study
To the best of our knowledge, this study is the first randomised 
controlled trial to compare the long-term clinical effectiveness 
and cost-effectiveness of levetiracetam versus valproate for 
patients with newly diagnosed generalised or unclassified 
epilepsy. The study is pragmatic in design and recruited a 
cohort of participants aged over 5 years from routine UK 
National Health Service clinics, and the results are relevant to 
every day clinical practice.
Levetiracetam did not meet our definition of non-inferiority 
for time to 12-month remission compared with valproate 
and it was inferior for times to treatment failure, 2-year 
remission from seizures, and first subsequent seizure. 
In addition, levetiracetam was not found to be a cost-
effective alternative.
Implications of all the available evidence
For people with generalised epilepsies, the available evidence 
identifies valproate as more clinically effective and cost-
effective than lamotrigine and levetiracetam. Ethosuximide 
and valproate have similar efficacy for absence epilepsies but 
ethosuximide is inefficacious for other seizure types 
(ie, generalised tonic-clonic seizures and myoclonic seizures). 
For men, valproate should remain a first-line treatment for 
generalised epilepsies. For women, there should now be 
further debate to inform practice and policy about avoiding 
the most effective treatment to minimise the potential risk of 
harm in future pregnancies.
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RCTs of efficacy as an add-on treatment for some 
generalised seizure types,16,17 and evidence of tolerability 
as monotherapy compared with valproate,18 there is no 
evidence from RCTs of the clinical efficacy or cost-
effectiveness of levetiracetam when used as monotherapy 
or as first-line treatment in patients with generalised or 
unclassifiable epilepsy.
Valproate is not recommended for women of child-
bearing potential as it is associated with a congenital 
major malformation rate of around 10%.15 Moreover, up 
to a third of children exposed to valproate in utero have a 
significant reduction in their IQ16 and are at increased 
risk of autism spectrum disorder.19 In 2017, the European 
Medicines Agency and the UK Medicines and Healthcare 
Products Regulatory Agency launched a pregnancy 
prevention programme,20 stating that women should not 
be prescribed valproate unless other treatments are 
ineffective or not tolerated. For women with an idiopathic 
generalised epilepsy, the two main alternatives are 
lamotrigine, which is less effective but safer in pregnancy, 
and levetiracetam, which has increasing evidence to 
support its safety in pregnancy,21,22 but its effectiveness 
compared with valproate is unknown.
The aim of SANAD II was to compare the long 
term clinical effectiveness and cost-effectiveness of 
levetiracetam compared with valproate in participants with 
newly diagnosed generalised or unclassifiable epilepsy.
Methods
Study design and participants
SANAD-II was a phase 4, multicentre, open-label, 
randomised controlled trial run in the UK National Health 
Service (NHS) adult neurology and paediatric services. 
85 hospital centres were opened, of which 69 recruited 
participants to this trial. Participants were eligible for 
recruitment if they were aged 5 years or older, had a 
history of at least two unprovoked epileptic seizures 
requiring treatment, their clinical epilepsy diagnosis was a 
generalised epilepsy syndrome or was unclassifiable, and 
had never been treated with an anti-seizure medicine 
(except for emergency treatment in the 2 week period 
before enrolment). Exclusion criteria included having 
provoked or acute symptomatic seizures only, currently 
taking anti-seizure medicine treatment, and having 
known progressive neurological disease. Epileptic seizures 
and syndromes were classified according to International 
League Against Epilepsy classifications3,4 on the basis 
of seizure semiology and electro encephalogram (EEG) 
results. Instances in which the precise idiopathic gen-
eralised epilepsy syndrome was uncertain (eg, for patients 
with generalised tonic-clonic seizures and generalised 
spike and wave changes on their EEG), recruiting cli-
nicians were able to classify such patients as having 
idiopathic generalised epilepsy not specified. SANAD II 
was granted ethics approval from the North West-Liverpool 
East Research Ethics Committee on June 7, 2012. The trial 
protocol has been previously published.23
Randomisation and masking
After providing consent, participants were randomly 
allocated (1:1) to receive either levetiracetam or valproate. 
We used a secure, centrally controlled, 24h web-based 
facility to implement a minimisation program with a 
random element utilising factors, which were not made 
known to reduce the risk of predicting allocation. These 
factors were centre, sex (ie, male or female), and number 
of previous seizures (ie, 2, 3–5, 6+), which were not 
made known. Recruiting clinicians were required to 
initiate trial treatment within 7 days of randomisation. 
Participants and investigators were not masked were 
aware of treatment allocation.
Procedures
Trial treatments were prescribed as per routine NHS 
practice and dispensed by hospital and community 
pharmacies, and clinicians prescribed the formulation 
they considered most appropriate. The trial protocol 
provided guidance on initial drug titration and main-
tenance doses based on routine practice, although 
clinicians were able to tailor these as appropriate. All 
medications were taken orally. For participants aged 
12 years or older, the initial advised maintenance doses 
were 500 mg twice per day for both levetiracetam and 
valproate. For children aged 5–12 years, the initial daily 
maintenance doses advised were 25 mg/kg for valproate 
and 40 mg/kg for levetiracetam. Subsequent dose and 
treatment changes at follow-up visits were made on the 
basis of treatment response and in accordance with 
routine clinical practice.
We aimed to complete recruitment over a 4·5 year 
period and to then follow up the trial cohort for a further 
2 years, allowing a minimum follow-up of 2 years and 
maximum of 6·5 years. Patients were followed up 
according to clinical need, and minimum trial visits were 
expected at 3, 6, and 12 months, and annually thereafter. 
At visits, data were collected for seizures, anti-seizure 
medication, and adverse reactions. Participants con-
tinued in follow-up whether they were still taking their 
allocated treatment or not. When participants fell out of 
hospital follow-up, outcome data were sought from their 
general practitioner.
For adults, QOL outcomes were assessed using 
subscales of the quality of life in newly diagnosed epilepsy 
battery (NEWQOL) and the Impact of Epilepsy Scale.24 For 
children and adolescents aged younger than 16 years, 
QOL assessment involved both patient and parent-based 
measures: children aged 8–15 years completed a generic 
health status measure validated for use in epilepsy, the 
KINDL;25 and the epilepsy impact and attitude to epilepsy 
subscales of the Quality of Life in Epilepsy Inventory 
for Adolescents (QOLIE-AD).26 Parents of all children 
completed proxy QOL questionnaires. QOL questionnaires 
were completed at baseline and annually thereafter. 
Adults and parents also completed a subset of QOL 
measures at 3 months and 6 months.
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Adult and adolescent participants were asked to complete 
the EQ-5D-3L and the EuroQol visual analogue scale 
(EQ-VAS); participants aged 8–15 completed the EQ-VAS 
and self-reported youth EQ-5D-3L-Y, or if not available, 
proxy EQ-5D-3L, which was completed by a parent or carer. 
For participants aged 5–7 years, only proxy questionnaires 
were administered. Participants’ resource-use associated 
with secondary care (ie, inpatient, outpatient, and accident 
and emergency care), other health-care and social services 
(ie, primary care and community services), and medicines 
were measured using routine hospital episode statistics, 
resource-use questionnaires,27 and case report form 
records. Resource-use was valued in monetary terms 
(measured in pounds sterling using national unit costs 
for 2019–20) using national unit costs.27–30
Outcomes
The primary outcome was time to 12-month remission 
from seizures, calculated as days from randomisation to 
the first date at which a period of 12 months had elapsed 
without any seizures. The secondary seizure outcomes 
were time to 24-month remission and time to first 
subsequent seizure. There were three secondary outcomes 
for treatment failure: (1) time to treatment failure overall, 
defined as days from randomisation to a decision to 
withdraw the randomised drug or to add a new anti-
seizure medication because of either inadequate seizure 
control or unacceptable adverse reactions; (2) time to 
treatment failure due to inadequate seizure control alone; 
and (3) time to treatment failure due to unacceptable 
adverse reactions alone. The other secondary outcomes 
were adverse reactions, QOL, and health economic 
outcomes based on incremental costs and quality-adjusted 
life-years (QALYs) gained. At clinic visits, data were 
collected on adverse reactions reported by the patient and 
the investigators assessment stated whether the event was 
possibly, probably, or almost certainly related the anti-
seizure medication. These adverse reactions were coded 
using the MedDRA dictionary.
Statistical analysis
SANAD-II was designed to detect non-inferiority of 
levetiracetam compared with valproate for the primary 
outcome of time to 12-month remission. The International 
League Against Epilepsy commission on antiepileptic 
drugs defined limits of equivalence of ±10% for the 
primary outcome in antiepileptic drug monotherapy 
studies.28 Calculations were informed by the SANAD I 
study,14 which estimated the 12-month remission free 
probability (at 24 months) as 0·31 (exponential hazard 
rate of 0·0488) for valproate. Assuming a 10% absolute 
difference in survival probability, the non-inferiority 
margin on the hazard ratio (HR) scale was ln(0·31)/
ln(0·41)=1·314. Therefore, assuming a HR of 1, 
80% power, and a one-sided alpha of 0·025, 260 patients 
were required in each of two treatment groups, allowing 
for 5% losses to follow-up, as occurred in SANAD-I 
(520 patients in total).
Primary analyses were undertaken on an intention-to-
treat (ITT) basis. We used a 0·05 level of significance and 
95% CIs throughout. The statistical and health economic 
analysis plans were developed before doing final analyses 
and are available in appendix 1 and appendix 2. Analyses 
were done using SAS software (version 9.4; SAS Institute, 
Cary, NC, USA). Completeness of follow-up statistics 
were calculated as the total number of days follow-up for 
all participants as a percentage of the total potential 
number of days follow-up.29
Time to event outcomes were summarised by Kaplan-
Meier curves for each treatment group and Cox 
proportional hazards regression models explored using 
two different models: (1) the primary analysis, including 
the treatment effect only; and (2) including the treatment 
together with gender (ie, male or female), number of 
seizures before randomisation (ie, 2, 3–5, 6+), and random 
effects for centre. Models were also fitted to include a 
stratification variable for epilepsy type (ie, generalised or 
unclassified epilepsy). The assumption of proportional 
hazards was investigated by examining Schoenfeld resid-
ual plots and incorporating time-dependent covariates in 
all models. If the assumption of proportional hazards 
was not valid, an additional extended Cox model with 
time-dependent covariates was used. Subgroup effects 
(for patients with absence epilepsies, other generalised 
epilepsies, or unclassified epilepsy) were explored in a 
post-hoc analysis by adding treatment-covariate interaction 
terms to the primary Cox model. All treatment effects 
were presented as a HR with a two-sided 95% CI of 
valproate compared with levetiracetam. For the primary 
outcome (ie, 12-month remission) non-inferiority 
hypothesis, the upper limit of the 95% CI needed to be 
less than 1·314 to conclude non-inferiority.
Figure 1: Trial profile
Data on non-randomised patients were not collected. ITT=intention-to-treat.
260 allocated to receive valproate 
260 included in ITT analysis
520 patients randomly assigned
3 did not receive allocated
   intervention
5 excluded from
    per-protocol analysis 
    2 not epilepsy
    3 major treatment 
       protocol deviation
 
 
260 allocated to receive levetiracetam 
260 included in ITT analysis
2 did not receive allocated
   intervention
6 excluded from 
    per-protocol analysis 
    3 not epilepsy
   3 major treatment
       protocol deviation
 
 
255 included in per-protocol analysis 254 included in per-protocol analysis
See Online for appendix 1
See Online for appendix 2
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A per-protocol (PP) analysis of the primary outcome 
was also done using a Fine and Gray model,30 with 
treatment failure included as a competing risk, and 
censoring participants with drug failure before achieving 
remission. This analysis excluded participants with major 
protocol deviations, participants given an alternative 
diagnosis to epilepsy after random assignment, and 
participants who did not receive the drug at all.
For time to treatment failure, a competing risks 
analysis, using the Fine and Gray model,30 was done to 
assess the two main reasons for treatment failure (ie, 
inadequate seizure control and unacceptable adverse 
reactions).31 Cumulative incidence curves are presented 
for each treatment group.
The difference in QOL measures between treatment 
groups was estimated for each population (ie, children, 
adults, and parent-carers) and for each outcome 
applicable within that population by fitting a repeated 
measures random effects model with a baseline QOL 
variable, treatment group, and time in days using spatial-
power covariance structure for repeated measures and 
unstructured covariance for the random effect.
Analysis sets for the summary of adverse reactions 
included all patients who received any dose of a study 
drug. All adverse reactions and serious adverse reactions 
were coded using the MedDRA dictionary. The number 
(and percentage) of patients experiencing each reaction, 
and the number (and percentage) of occurrences of each 
reaction are presented with no formal statistical testing 
undertaken.
Interim monitoring was done by an independent data 
safety monitoring committee, meeting approximately 
annually. This process included analyses of the primary 
outcome and five of the secondary outcomes (all using 
the Haybittle-Peto approach).
The economic analysis (shown in appendix 2) adopted 
the costing perspective of the NHS and personal social 
services and was done using data up to 24 months of 
follow-up. Missing cost and QALY data were imputed 
using multiple imputation with chained equations.32 
Based on the imputed data, differences between treat-
ment groups in total costs and QALYs were compared 
with reference to bootstrapped central ranges, based on 
10 000 repli cations. In the base-case analysis, total costs 
and QALYs (with year 2 discounted at 3·5%) were 
adjusted using linear regressions33 for treatment 
allocation, baseline costs or utility, age, sex, and epilepsy 
clas sification, with centre as random effects. Incremental 
costs and QALYs were estimated to identify dominance 
and calculate the incremental net health benefit as the 
difference in QALYs between treatments, minus the 
difference in costs multiplied by the cost-effectiveness 
threshold (£20 000 per QALY).34 The joint uncertainty in 
incremental costs and QALYs was expressed in terms of 
the probability of each treatment being cost-effective at 
the threshold. Sensitivity analyses comprised alternative 
discount rates, use of complete cases, PP cohort, QALYs 
based on the NEWQOL-6D35 and EQ-VAS, and were 
based on unadjusted analysis. A subgroup analysis 
considered cost-effectiveness in children, adults, and 
adolescents aged 16 years or older at the point of ran-
domisation. QALYs were calculated on the basis of the 








Median (IQR) 13·6 (8·8–19·7) 14·1 (9·1–19·8) 13·9 (8·9–19·7)
Range 5·0–94·4 5·0–83·9 5·0–94·4
Age group, years
5–7 52 (20%) 48 (18%) 100 (19%)
8–11 54 (21%) 56 (22%) 110 (21%)
12–15 54 (21%) 48 (18%) 102 (20%)
16–29 70 (27%) 81 (31%) 151 (29%)
≥30 30 (12%) 27 (10%) 57 (11%)
Gender
Male 167 (64%) 170 (65%) 337 (65%)
Female 93 (36%) 90 (35%) 183 (35%)
Previous or current neurological disorder
Stroke or cerebrovascular 0 0 0
Cerebral haemorrhage 0 2 (1%) 2 (<1%)
Intracranial surgery 0 2 (1%) 2 (<1%)
Head injury* 1 (<1%) 1 (<1%) 2 (<1%)
Meningitis or encephalitis 4 (2%) 0 4 (1%)
Cortical dysplasia or developmental anomaly 0 0 0
Other 11 (4%) 13 (5%) 24 (5%)
History
Learning disability 22 (8%) 29 (11%) 51 (10%)
Febrile convulsions 21 (8%) 23 (9%) 44 (8%)
Any other acute symptomatic seizures 4 (2%) 10 (4%) 14 (3%)
Family history in primary relatives 49 (19%) 50 (19%) 99 (19%)
Neurological deficit 6 (2%) 10 (4%) 16 (3%)
Epilepsy type
Generalised epilepsy 201 (77%) 196 (75%) 397 (76%)
Unclassified epilepsy 59 (23%) 64 (25%) 123 (24%)
Epilepsy syndrome (generalised epilepsy only)†
Childhood absence 52 (26%) 52 (27%) 104 (26%)
Juvenile absence 22 (11%) 14 (7%) 36 (9%)
Juvenile myoclonic 24 (12%) 27 (14%) 51 (13%)
Epilepsy with tonic-clonic seizures on 
awakening
11 (5%) 12 (6%) 23 (6%)
Other idiopathic generalised epilepsy not 
specified‡
90 (45%) 90 (46%) 180 (45%)
Other epilepsy syndrome 10 (5%) 7 (4%) 17 (4%)
Total number of seizures reported
Median 10 (3–99+) 10 (3–99+) 10 (3–99+)
Missing 1 5 6
Days since most recent seizure
Median 4 (0–26) 4 (0–25) 4 (0–26)
Range 0–223 0–211 0–223
Missing 2 5 7
(Table 1 continues on next page)
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EuroQol 5-dimension 3-level (EQ-5D-3L) question-
naire, and applying the UK tariff scores.25 This trial is 
registered with the ISRCTN registry, 30294119 (EudraCt 
Number: 2012-001884-64).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
The first participant was randomly assigned on 
April 30, 2013, and the last participant was randomly 
assigned on Aug 2, 2016, after which every effort was 
made to follow up the trial cohort for a further 2 years. 
The last participant visit was on Jan 13, 2019. 69 UK 
centres recruited between one and 40 patients each and 
randomly assigned a total of 520 participants, 260 to start 
treatment with levetiracetam and 260 to start treatment 
with valproate (figure 1). Baseline characteristics were 
well balanced across treatment groups (table 1). The 
median age of participants was 13·9 years (IQR 8·9–19·7) 
with a predominance of male participants (65%) showing 
concern about randomly assigning female participants 
to valproate. Approximately 10% of participants (51 par-
ticipants) had a learning disability, 16 (3%) participants 
had a neurological deficit, and 99 (19%) participants had a 
first degree relative with epilepsy. Approximately 
three-quarters of the participants (397 par ticipants) had 
generalised epilepsy and the remainder of the participants 
(123 participants) had unclassifiable epilepsies. Of those 
with generalised epilepsy, 104 (26·2%) had childhood 
absence epilepsy, 36 (9·1%) had juvenile absence epilepsy, 
51 (12·8%) had juvenile myoclonic epilepsy, 23 (5·8%) 
had generalised epilepsy with tonic-clonic seizures on 
waking, and 180 (45·3%) were classified as idiopathic 
generalised epilepsy not specified. Participants were 
randomly assigned a median of 4 days (0–26) after their 
most recent seizure.
The completeness of follow-up statistics for the primary 
outcome was 87% for valproate and 83% for levetiracetam. 
In this analysis, the median days of follow-up was 427 
(IQR 365–731) for valproate and 550 (366–781) for 
levetiracetam; follow-up was shorter for valproate as 
participants allocated valproate achieved the primary 
outcome sooner. Estimates for the primary and secondary 
analyses are provided in appendix 3 (p 1).
The ITT analysis of time to 12-month remission did not 
find non-inferiority of levetiracetam compared with 
valproate as the 95% CI for the HR (1·19 [95% CI 
0·96–1·47] unadjusted, 1·23 [0·99–1·52] adjusted) 
includes the pre-defined non-inferiority margin of 1·314. 
Consequently, the possibility of a clinically important 
difference could not be excluded. There is crossing of the 
Kaplan-Meier survival curves (figure 2) and evidence of 
non-equality of hazard ratios across time (p=0·001), 
violating the assumption of proportional hazards. 
Interval specific HR estimates (appendix 3 p 1) indicate 
significant benefit of valproate within the first year, but 
not in subsequent years. Annual differences in 12-month 
remission probabilities, for example, that at 1 year, 
9% fewer patients had entered 12-month remission 
on levetiracetam than on valproate are shown in 
appendix 3 (p 2). The Kaplan-Meier estimate of the 
median time to achieve 12-month remission was also 
shorter for valproate (445 days [95% CI 406–531]) than 
for levetiracetam (636 days [553–728]).
The PP analyses (Fine and Gray model) for time to 
12-month remission (appendix 3 p 3) excluded patients 
with major protocol deviations (6; 1%) and patients whose 
epilepsy diagnosis was a misdiagnosis (5; 1%) and 
accounted for treatment failures before achieving 
12-month remission (82 [32%] participants in the valproate 
group and 121 [47%] participants in the levetiracetam 
group). The per-protocol analysis showed that 12-month 
remission was superior with valproate than with 
levetiracetam; although this trial was powered for non-
inferiority, it was also designed to show superiority. 
Furthermore, the assumption of a constant HR across 
time appeared reasonable in the PP analysis, suggesting 
that treatment failures before remission largely explain 
the non-constant effect seen in the ITT analysis.
Subgroup effects were explored in a post-hoc analysis 







(Continued from previous page)
Age at first seizure, years
Median 12 (7·2–18) 13 (8·3–18) 13 (7·8–18)
Range 0·5–93 0·2–80 0·2–93
Missing 3 7 10
Interval between first and most recent seizure, days
Median 203 (98–665) 250 (110–603) 228 (100–648)
Range 0–16 136 0–19 662 0–19 662
Missing 3 7 10
EEG
EEG not done 20 (8%) 24 (9%) 44 (8%)
EEG normal 58 (22%) 51 (20%) 109 (21%)
Non-specific abnormality 11 (4%) 9 (3%) 20 (4%)
Generalised abnormality (slow wave activity 
with spiking)
138 (53%) 133 (51%) 271 (52%)
Generalised abnormality (slow wave activity 
without spiking)
8 (3%) 7 (3%) 15 (3%)
Focal abnormality (paroxysmal slow activity 
with spiking)
10 (4%) 8 (3%) 18 (3%)
Focal abnormality (paroxysmal slow activity 
without spiking)
2 (1%) 7 (3%) 9 (2%)
Other 13 (5%) 21 (8%) 34 (7%)
Data are n (%) or median (IQR), unless otherwise stated. EEG=electroencephalogram. *Post-traumatic amnesia lasting 
over 24 h or compound depressed fracture. †More than one category could be selected. ‡150 (83%) of 180 patients in 
this group reported tonic-clonic seizures. 
Table 1: Baseline characteristics
See Online for appendix 3
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for initiating valproate in participants with other idio-
pathic generalised epilepsies (HR 1·55 [95% CI 
1·14–2·11]) whereby the difference in immediate 
12-month remission rates were 19·1% (6·6–31·7), but 
not for absence epilepsies (HR 0·90 [0·60–1·35]), or 
unclassified epilepsy (1·07 [0·69–1·67])
Valproate was shown to be superior to levetiracetam for 
time to 24-month remission (using ITT analysis; HR 1·43 
[95% CI 1·06 to 1·92]). Again, there was a crossing of 
the Kaplan-Meier survival curves (appendix 3 p 5) and 
evidence against an assumption of proportional hazards 
(p=0·002). At 24 months follow-up, the difference in 
24-month remission rates was 12% (4 to 20), diminishing 
to 4% (–8 to 17) at 4 years.
Valproate was superior to levetiracetam for time to first 
seizure (HR 0·82 [95% CI 0·67–1·00]; appendix 3 p 6) 
and there was insufficient evidence against an assump-
tion of proportional hazards (p=0·39). Valproate was also 
superior to levetiracetam for time to treatment failure for 
any reason (figure 3; 0·65 [0·50–0·83]) with insufficient 
evidence against an assumption of pro portional hazards 
(p=0·22). Annual treatment failure rates and differences 
in failure rates between valproate and levetiracetam 
are shown in appendix 3 (p 7). At 2 years there was a 
15% (6–23) difference in the treatment failure rate for 
levetiracetam compared with valproate. The doses taken 
at treatment failure or at the point of last follow-up 
are summarised in appendix 3 (p 8), and the findings 
indicate that reasonable dose ranges were tried before 
deciding failure had occurred.
Analysis of the two main reasons for treatment failure 
found valproate to be superior to levetiracetam for 
treatment failure due to inadequate seizure control 
(HR 0·43 [95% CI 0·30–0·63]), but no difference 
between groups was found for treatment failure due 
to unacceptable adverse reactions (0·93 [0·61–1·40]; 
appendix 3 p 9.
SANAD II recorded data for adverse reactions that were 
judged by the treating clinicians to be possibly, probably, 
or definitely caused by anti-seizure medicines. The safety 
analysis included the 258 participants who were randomly 
assigned to levetiracetam and the 257 participants who 
were randomly assigned to valproate and who received 
at least one dose of their allocated treatment. Adverse 
reactions according to the MedRA system organ classifi-
cation are shown in table 2, and adverse reactions by 
MedRA preferred term are given in appendix 3 (p 10). 
There were 220 adverse reactions in 96 (37%) participants 
who were randomly assigned to valproate and 223 adverse 
reactions in 107 (41%) participants who were randomly 
assigned to levetiracetam (table 2). There were more 
psychiatric symptoms reported in participants allocated to 
levetiracetam (109 events reported in 66 [26%] participants) 
compared with valproate (54 events reported in 36 [14%] 
participants). There were more reports of weight gain with 
valproate (26 [10%] participants) than with levetiracetam 
(eight [3%] participants); appendix 3 p 10. Of those 
randomly assigned to valproate, ten (4%) participants had 
a total of 15 severe adverse reactions and of those randomly 
assigned to levetiracetam, ten (3·9%) partici pants had a 
total of 16 severe adverse reactions (appendix 3 p 13). 
For two (1%) patients who were randomly assigned to 
valproate and four (2%) patients who were randomly 
assigned to levetiracetam, the adverse reactions were 
classified as serious. None were classified as suspected 
unexpected serious adverse reactions. There were two 
deaths, one in each group, that were unrelated to trial 
treatments. One participant randomly assigned to initiate 
valproate became pregnant. The pregnancy was conceived 
while taking levetiracetam monotherapy and resulted in 
a healthy baby without any malformations at postnatal 
examination. Nine participants randomly assigned to 
levetiracetam reported a pregnancy with four healthy 
babies at postnatal examination, three miscarriages (all of 
whom were taking levetiracetam at the time of reporting 




































































HR valproate vs levetiracetam 1·19 (0·96–1·47)



































































HR valproate vs levetiracetam 0·65 (0·50–0·83)
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pregnancy), one baby with low birthweight (levetiracetam 
taken at the time of reporting pregnancy) and one baby 
with major malformations (carbamazepine taken at the 
time of reporting pregnancy).
221 participants returned a baseline questionnaire and at 
least one follow-up questionnaire and were included in the 
QOL analysis. For participants who provided QOL data, 
the mean follow-up time was 695 days (SD 445) and the 
maximum was 1883 days. Participants who were not 
included in this analysis were more likely to be male than 
female (71% vs 57%) and have unclassified epilepsy than 
generalised epilepsy (27% vs 19%). Results from the 
repeated measures random effects models (appendix 3 
p 14) suggested there might be small differences in favour 
of levetiracetam for QOL emotional (child), family (child 
and parent), and school (child) domains. However, because 
of the high level of missing data, these results cannot 
be considered reliable. We did not consider imputation 
reasonable because of the high level of missing data.
Health economic analysis data were available for 
412 participants, and self-reported resource-use data were 
available for 243 participants at 3 months, 212 participants 
at 6 months, 185 participants at 12 months, and 148 par-
ticipants at 24 months. Most of the costs were related to 
hospital outpatient clinic attendance, admitted care, 
and anti-seizure medications (appendix 3 p 15). Total, 
unad justed costs for participants randomly assigned to 
levetiracetam were £4267 (95% central range [CR] 
3944 to 5462), compared with £4205 (3827 to 4956) for 
valproate. The difference of £61 (–651 to 1230) was not 
significant. In the adjusted, base-case analysis, total 
costs were £4350 (4136 to 5623) for levetiracetam, 
compared with £4246 (3979 to 5090) for valproate (table 3). 
These results correspond to an incremental cost of 
£104 (–587 to 1234).
EQ-5D utilities were available for 274 participants at 
baseline, and they could be calculated for 161 participants 
at 12 months and for 128 participants at 24 months. 
Levetiracetam was associated with 1·603 QALYs 
(1·500 to 1·631) in the base-case analysis, compared with 
1·637 QALYs (1·565 to 1·673) for valproate. This difference 
corresponded to an incremental QALY of –0·035 QALYs 
(–0·137 to 0·032). Levetiracetam was therefore dominated 
by valproate and was associated with a negative incre-
mental net health benefit of –0·040 QALYs (–0·175 to 0·037) 
at a cost-effectiveness threshold of £20 000 per QALY. The 
probability of levetiracetam being cost-effective at this 
threshold was 0·17. Incremental net health benefits were 
similarly negative for both subgroups (table 3). Sensitivity 
analyses are provided in appendix 4 (pp 26–30).






Psychiatric disorders 54 109 36 (14%) 66 (26%)
Nervous system disorders 58 46 42 (16%) 37 (14%)
Gastrointestinal disorders 24 20 19 (7%) 15 (6%)
Investigations 31 11 29 (11%) 11 (4%)
General disorders and administration site conditions 20 17 16 (6%) 15 (6%)
Metabolism and nutrition disorders 19 8 19 (7%) 8 (3%)
Skin and subcutaneous tissue disorders 11 6 11 (4%) 5 (2%)
Blood and lymphatic system disorders 1 1 1 (<1%) 1 (<1%)
Eye disorders 1 1 1 (<1%) 1 (<1%)
Respiratory, thoracic, and mediastinal disorders 0 2 0 2 (1%)
Congenital, familial, and genetic disorders 0 1 0 1 (<1%)
Immune system disorders 1 0 1 (<1%) 0
Injury, poisoning, and procedural complications 0 1 0 1 (<1%)
Table 2: Adverse reactions by the MedRA system organ classification
Levetiracetam Valproate Incremental
Base-case all participants (n=520)
Total costs (£) 4350 (4136 to 5623) 4246 (3979 to 5090) 104 (–587 to 1234)
QALYs 1·603 (1·500 to 1·631) 1·637 (1·565 to 1·673) –0·035 (–0·103 to 0·077)
Net health 
benefit at 
£20 000 per 
QALY (QALYs)
1·385 (1·236 to 1·410) 1·425 (1·323 to 1·464) –0·040 (–0·175 to 0·037)
Children aged <16 years (n=312)
Total costs (£) 4336 (4017 to 5516) 4360 (4046 to 5149) –24 (–752 to 1065)
QALYs 1·624 (1·506 to 1·646) 1·626 (1·554 to 1·667) –0·002 (–0·123 to 0·054)
Net health 
benefit at 
£20 000 per 
QALY
1·407 (1·254 to 1·430) 1·408 (1·307 to 1·455) –0·002 (–0·136 to 0·062)
Adults and adolescents aged ≥16 years (n=208)
Total costs (£) 4316 (3842 to 5898) 3957 (3525 to 5161) 359 (–644 to 1640)
QALYs 1·576 (1·474 to 1·636) 1·654 (1·563 to 1·693) –0·078 (–0·175 to 0·015)
Net health 
benefit at 
£20 000 per 
QALY
1·407 (1·200 to 1·425) 1·456 (1·330 to 1·497) –0·090 (–0·208 to 0·018)
Data are mean (95% CI). QALY=quality-adjusted life-years.
Table 3: Results of the adjusted base-case and subgroup analyses
See Online for appendix 4
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Discussion
SANAD II found that levetiracetam is neither clinically 
effective nor cost-effective compared with valproate in 
patients with newly diagnosed generalised or unclas-
sified epilepsy. This pragmatic, multicentre, open-label, 
randomised trial was powered to assess non-inferiority 
of levetiracetam compared with standard treatment, 
valproate, in patients with newly diagnosed generalised 
and unclassified epilepsy. Levetiracetam did not meet 
our non-inferiority definition for time to 12-month 
remission from seizures. We found a 9% (95% CI 1–18) 
higher immediate 12-month remission rate with 
valproate (26% vs 36%), but the difference between 
treatment policies diminished over time as dose and 
treatment changes were made. Levetiracetam was 
inferior to valproate for time to treatment failure, time 
to 2 year remission, and time to first subsequent 
seizure. Treatment failure due to inadequate seizure 
control was more likely with levetiracetam than with 
valproate (HR 0·43 [0·30–0·63]). Inadequate seizure 
control leading to treatment change was the likely 
explanation for finding non-proportional hazards in 
the primary ITT 12-month remission analysis. The PP 
analysis, which took treatment failure into account, 
found valproate to be superior to levetiracetam (1·68 
[1·30–2·15]). These results are particularly important 
when considering treatment choices for women of 
childbearing potential.
To explore the treatment effects further, the cohort was 
split into three groups: participants with absence 
epilepsies, participants with other generalised epilepsies, 
and participants with unclassified epilepsy. For time to 
12-month remission, our results indicated a meaningful 
advantage for starting valproate in the so-called other 
generalised epilepsy group, for which the difference in 
immediate remission rate was 19·1% (95% CI 6·6–31·7), 
whereas there was no clear advantage seen in the absence 
or unclassified epilepsy subgroups. Participants with 
other generalised epilepsies were mainly those with 
generalised tonic-clonic seizures, for whom seizure rates 
are low and many months of observation are typically 
required to record seizures and make incremental 
changes to dose and drug. Conversely, participants with 
absence seizures typically have a high seizure rate, 
enabling more rapid decisions about dose and drug 
changes to gain early seizure control.
The number of female participants recruited (n=80) 
between the age of 12 and 50 years was lower than the 
number of men recruited (n=218) and the European 
Medicines Agency and the Medicines and Healthcare 
Products Regulatory Agency pregnancy prevention 
scheme was implemented following the commencement 
of the study and during most of its recruitment and 
follow-up period. There were ten pregnancies during the 
study, none of which were exposed to valproate, and only 
one of these women was randomly assigned to initiate 
valproate.
Analysis of QOL outcomes did not indicate benefit for 
either drug, but the return rate of questionnaires was 
disappointingly low. The cost utility analysis found that 
levetiracetam was not cost-effective compared with 
valproate at thresholds of cost-effectiveness operating in 
the UK NHS. Levetiracetam was associated with fewer 
QALYs and higher costs than valproate. The finding of a 
negative incremental net health benefit for levetiracetam 
compared with valproate was consistent for both adult 
and children subgroups and was stable in most sensitivity 
analyses, apart from two that were limited by the missing 
data in NEWQOL-6D utilities and costs.
This study has several important limitations. Data for 
the occurrence of seizures were collected using seizure 
diaries and reports at clinic visits and it is possible that 
seizures were missed or not reported. SANAD II was 
open-label, which might have influenced decisions about 
dose and treatment changes, thereby biasing results for 
time to treatment failure, seizure outcomes, and the 
reporting of adverse reactions. Although 397 (76%) 
participants were classified as having a generalised 
epilepsy, only 271 (52%) had generalised spike and 
wave changes on their EEG, indicating that some of 
the remaining 24% of participants might have been 
misclassified. It is not possible to state whether this 
factor might have increased or diminished the treatment 
effects observed, but it is interesting to note that in 
the subgroup analysis for 12-month remission the 
estimate in participants who were unclassified favoured 
levetiracetam. In addition, other than for participants 
with absence epilepsies, the number of participants 
classified with a specific generalised epilepsy syndrome 
at the time of random assignment was small, precluding 
subgroup analyses for syndromes, such as juvenile 
myoclonic epilepsy.
Additionally, more men than women were recruited 
(64·8% vs 35·2%), which could have introduced unin-
tended bias into the study. Although there is no reason to 
expect important differences in clinical effectiveness by 
gender,7 differing approaches to dosing and treatment 
choices for men and some women could influence 
seizure remission rates, adverse events, and decisions 
about treatment failure. There was also a low return rate 
for questionnaires, which diminished our ability to 
identify QOL consequences and also affected the 
economic analysis. For costs, the use of free text 
questions might have introduced bias, as also the 
assumption that unanswered questions implied no 
use of resources. However, these issues were largely 
mitigated by more complete data for the costs of hospital 
care and anti-seizure medicines, which were more 
difficult to recall while also being the main cost drivers. 
For QALYs, this issue was mitigated by use of area under 
the curve methodology, in which QALYs could be 
calculated provided two or more EQ-5D questionnaires 
had been returned. Our use of the EQ-5D-3L-Y and proxy 
version of the EQ-5D-3L was limited by having to apply 
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the adult tariff for estimating utilities from EQ-5D 
profiles. This requirement represents a weakness in 
many economic evaluations of interventions in paedi-
atric populations,36 although a valuation of children’s 
EQ-5D-3L-Y health states should soon be available.37
These results should be put into context with previous 
studies, although few studies have assessed the long 
term effectiveness of treatments for patients with 
generalised epilepsies. SANAD I14 identified valproate as 
a first-line treatment as it was superior to lamotrigine for 
seizure control and superior to topiramate for treatment 
failure.10 An individual participant data network meta-
analysis,13 which included data from SANAD I, failed to 
show superiority for 12-month remission in participants 
with generalised epilepsy of any drug among valproate, 
levetiracetam, gabapentin, phenytoin, carbamazepine, 
oxcarbazepine, topiramate, or phenobarbital, but the 
results were heavily confounded by classification errors 
and the possible inclusion of participants with focal 
epilepsy. Valproate was superior to carbamazepine, 
topiramate, and phenobarbital for treatment failure. 
A clinical trial14 in participants with absence epilepsies 
found valproate and ethosuximide superior to 
lamotrigine for treatment failure. To the best of our 
knowledge, SANAD II is the only trial that provides 
much needed head-to-head data for the long term 
effectiveness of valproate versus levetiracetam.
These results have important implications for clinical 
practice and research. For men with generalised onset 
seizures, valproate should continue as a first-line treat-
ment. For women of childbearing potential, levetiracetam 
was inferior to valproate, as is lamotrigine,14 the other 
commonly prescribed alternative. Regulators, guideline 
developers, clinicians, and patient groups should now 
consider the benefit-to-risk ratio of each treatment. 
Some women might prefer a drug with greater efficacy 
notwithstanding the risk of teratogenicity, while others 
might prefer one that is safer in pregnancy despite lower 
efficacy, as indicated in a previous discrete choice 
experiment,38 which found that women would accept 
a 5% reduction in 12-month remission probability for 
a 1% reduction in fetal abnormality. For people with 
unclassified epilepsy, the subgroup analysis found no 
significant difference between treatments, but estimates 
favour levetiracetam. Future studies should not group 
generalised and unclassified epilepsy together and the 
international epilepsy community should identify a 
better strategy for assessing treatment policies in this 
common scenario.
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